Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Adenocarcinoma Of The Gastroesophageal Junction Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction Overview | 12 | 1 |
| Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction Comparative Analysis | 13 | 1 |
| Adenocarcinoma Of The Gastroesophageal Junction Therapeutics under Development by Companies | 14 | 2 |
| Adenocarcinoma Of The Gastroesophageal Junction Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Adenocarcinoma Of The Gastroesophageal Junction Pipeline Products Glance | 17 | 3 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Adenocarcinoma Of The Gastroesophageal Junction Products under Development by Companies | 20 | 3 |
| Adenocarcinoma Of The Gastroesophageal Junction Products under Investigation by Universities/Institutes | 23 | 1 |
| Adenocarcinoma Of The Gastroesophageal Junction Companies Involved in Therapeutics Development | 24 | 29 |
| AB Science SA | 24 | 1 |
| AbbVie Inc | 25 | 1 |
| Advenchen Laboratories, LLC | 26 | 1 |
| Amgen Inc. | 27 | 1 |
| ArQule, Inc. | 28 | 1 |
| AstraZeneca Plc | 29 | 1 |
| Boehringer Ingelheim GmbH | 30 | 1 |
| Boston Biomedical, Inc. | 31 | 1 |
| Bristol-Myers Squibb Company | 32 | 1 |
| Cerulean Pharma, Inc. | 33 | 1 |
| Daiichi Sankyo Company, Limited | 34 | 1 |
| Dr. Reddy's Laboratories Limited | 35 | 1 |
| Eli Lilly and Company | 36 | 1 |
| F. Hoffmann-La Roche Ltd. | 37 | 1 |
| Ganymed Pharmaceuticals AG | 38 | 1 |
| Genentech Inc | 39 | 1 |
| Gilead Sciences, Inc. | 40 | 1 |
| Hutchison MediPharma Limited | 41 | 1 |
| Imugene Limited | 42 | 1 |
| Mebiopharm Co., Ltd. | 43 | 1 |
| MedImmune LLC | 44 | 1 |
| Merck &Co., Inc. | 45 | 1 |
| Merck KGaA | 46 | 1 |
| Millennium Pharmaceuticals Inc | 47 | 1 |
| Neopharm Ltd. | 48 | 1 |
| Novartis AG | 49 | 1 |
| Oncobiologics, Inc. | 50 | 1 |
| Panacea Biotec Limited | 51 | 1 |
| Sanofi | 52 | 1 |
| Adenocarcinoma Of The Gastroesophageal Junction Therapeutics Assessment | 53 | 12 |
| Assessment by Monotherapy Products | 53 | 1 |
| Assessment by Combination Products | 54 | 1 |
| Assessment by Target | 55 | 3 |
| Assessment by Mechanism of Action | 58 | 3 |
| Assessment by Route of Administration | 61 | 2 |
| Assessment by Molecule Type | 63 | 2 |
| Drug Profiles | 65 | 238 |
| AL-3818 Drug Profile | 65 | 2 |
| alpelisib Drug Profile | 67 | 3 |
| AMG-337 Drug Profile | 70 | 2 |
| atezolizumab Drug Profile | 72 | 14 |
| avelumab Drug Profile | 86 | 11 |
| AZD-4547 Drug Profile | 97 | 2 |
| AZD-6738 Drug Profile | 99 | 1 |
| BI-853520 Drug Profile | 100 | 1 |
| cabazitaxel Drug Profile | 101 | 2 |
| catumaxomab Drug Profile | 103 | 2 |
| Cellular Immunotherapy for Oncology Drug Profile | 105 | 1 |
| ceritinib Drug Profile | 106 | 5 |
| CRLX-101 Drug Profile | 111 | 11 |
| DS-8201 Drug Profile | 122 | 1 |
| durvalumab Drug Profile | 123 | 11 |
| durvalumab + tremelimumab Drug Profile | 134 | 4 |
| emibetuzumab Drug Profile | 138 | 2 |
| GS-5745 Drug Profile | 140 | 2 |
| ibrutinib Drug Profile | 142 | 26 |
| IMAB-362 Drug Profile | 168 | 2 |
| IMU-131 Drug Profile | 170 | 4 |
| ipatasertib Drug Profile | 174 | 2 |
| ipilimumab Drug Profile | 176 | 9 |
| JS-001 Drug Profile | 185 | 1 |
| LAG-525 Drug Profile | 186 | 1 |
| LY-3127804 Drug Profile | 187 | 1 |
| masitinib Drug Profile | 188 | 14 |
| merestinib Drug Profile | 202 | 2 |
| napabucasin Drug Profile | 204 | 7 |
| nimotuzumab Drug Profile | 211 | 4 |
| oxaliplatin Drug Profile | 215 | 2 |
| panitumumab Drug Profile | 217 | 5 |
| PDR-001 Drug Profile | 222 | 2 |
| pembrolizumab Drug Profile | 224 | 37 |
| pertuzumab Drug Profile | 261 | 6 |
| ramucirumab Drug Profile | 267 | 10 |
| SAR-408701 Drug Profile | 277 | 1 |
| savolitinib Drug Profile | 278 | 4 |
| serabelisib Drug Profile | 282 | 2 |
| sonidegib phosphate Drug Profile | 284 | 4 |
| tivantinib Drug Profile | 288 | 6 |
| trastuzumab biosimilar Drug Profile | 294 | 2 |
| trastuzumab biosimilar Drug Profile | 296 | 1 |
| trastuzumab biosimilar Drug Profile | 297 | 1 |
| trastuzumab biosimilar Drug Profile | 298 | 1 |
| trastuzumab biosimilar Drug Profile | 299 | 1 |
| tremelimumab Drug Profile | 300 | 3 |
| Adenocarcinoma Of The Gastroesophageal Junction Dormant Projects | 303 | 2 |
| Adenocarcinoma Of The Gastroesophageal Junction Discontinued Products | 305 | 1 |
| Adenocarcinoma Of The Gastroesophageal Junction Product Development Milestones | 306 | 13 |
| Featured News &Press Releases | 306 | 1 |
| Jun 07, 2016: Boston Biomedical Featured Clinical Posters on Cancer Stem Cell Pathway Inhibitor Napabucasin in Multiple Cancer Types at ASCO 2016 | 306 | 3 |
| May 19, 2016: Sumitomo Dainippon Pharma announces Clinical Data of Investigational anti-cancer drug Napabucasin in Multiple Cancer Types at ASCO 2016 | 309 | 1 |
| May 18, 2016: Boston Biomedical Announces Clinical Data on First-in-Class Investigational Cancer Stem Cell Pathway Inhibitor Napabucasin in Multiple Cancer Types at ASCO 2016 | 309 | 2 |
| May 18, 2016: Eli Lilly to Present data on VEGF Receptor 2 antagonist ramucirumab at ASCO | 311 | 2 |
| Jun 01, 2015: Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitor BBI608 in Multiple Cancer Types | 313 | 2 |
| May 18, 2015: AB Science announces that three clinical abstracts will be presented at the 2015 ASCO annual meeting | 315 | 2 |
| Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer | 317 | 2 |
| Appendix | 319 | 2 |
| Methodology | 319 | 1 |
| Coverage | 319 | 1 |
| Secondary Research | 319 | 1 |
| Primary Research | 319 | 1 |
| Expert Panel Validation | 319 | 1 |
| Contact Us | 319 | 1 |
| Disclaimer | 320 | 1 |